Expertise in
40
conditions

Dr. Frederick Briccetti

Hematology
Concord Hospital
250 Pleasant St, 
Concord, NH 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
40
conditions
Concord Hospital
250 Pleasant St, 
Concord, NH 

Overview

Frederick Briccetti is a Hematologist in Concord, New Hampshire. Dr. Briccetti is highly rated in 40 conditions, according to our data. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Paget Disease of the Breast, and Thrombocytopenia.

His clinical research consists of co-authoring 6 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology

Licenses

Internal Medicine in NH

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Martin's Point Generations
  • MEDICARE MAPD
  • OTHER MEDICARE
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
NH Healthy Families
  • EPO
  • MANAGED MEDICAID PLAN
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

Concord Hospital
250 Pleasant St, Concord, NH 03301
Other Locations
Office
40 Buttrick Rd # B, Londonderry, NH 03053

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Enrollment Status: Recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Pembrolizumab, Pemetrexed Disodium
Study Phase: Phase 3
A Randomized Phase II Trial of Adjuvant Trastuzumab Emtansine (T-DM1) Followed by Subcutaneous Trastuzumab Versus Paclitaxel in Combination With Subcutaneous Trastuzumab for Stage I HER2-positive Breast Cancer (ATEMPT 2.0)
A Randomized Phase II Trial of Adjuvant Trastuzumab Emtansine (T-DM1) Followed by Subcutaneous Trastuzumab Versus Paclitaxel in Combination With Subcutaneous Trastuzumab for Stage I HER2-positive Breast Cancer (ATEMPT 2.0)
Enrollment Status: Recruiting
Publish Date: November 13, 2025
Intervention Type: Drug
Study Drugs: Trastuzumab-Emtansine, Trastuzumab SC, Paclitaxel
Study Phase: Phase 2
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
postMONARCH: A Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib Plus Fulvestrant to Placebo Plus Fulvestrant in Participants With HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy
postMONARCH: A Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib Plus Fulvestrant to Placebo Plus Fulvestrant in Participants With HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy
Enrollment Status: Active_not_recruiting
Publish Date: January 16, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Fulvestrant
Study Phase: Phase 3
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Enrollment Status: Active_not_recruiting
Publish Date: December 22, 2025
Intervention Type: Other, Dietary supplement, Drug
Study Drugs: Bevacizumab, Oxaliplatin, Leucovorin calcium, Fluorouracil, Irinotecan hydrochloride, Irinotecan
Study Phase: Phase 3
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Enrollment Status: Active_not_recruiting
Publish Date: March 30, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Enrollment Status: Active_not_recruiting
Publish Date: March 17, 2025
Intervention Type: Drug
Study Drugs: Trastuzumab, Paclitaxel, Trastuzumab emtansine
Study Phase: Phase 2
Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: a Randomized Phase 3 Non-Inferiority Trial (IMAGINE)
Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: a Randomized Phase 3 Non-Inferiority Trial (IMAGINE)
Enrollment Status: Active_not_recruiting
Publish Date: January 15, 2025
Intervention Type: Drug
Study Drugs: Pembrolizumab, Nivolumab, Atezolizumab, Durvalumab, Avelumab
Study Phase: Phase 3
Harnessing Mobile Technology to Deliver Tailored, Brief Pain-CBT for Advanced Cancer Patients on Opioids for Pain
Harnessing Mobile Technology to Deliver Tailored, Brief Pain-CBT for Advanced Cancer Patients on Opioids for Pain
Enrollment Status: Completed
Publish Date: January 01, 2025
Intervention Type: Behavioral
Study Phase: Not Applicable
Genetic Testing for Breast, Ovarian, Pancreatic, and Prostate Cancers - GeneBOPP
Genetic Testing for Breast, Ovarian, Pancreatic, and Prostate Cancers - GeneBOPP
Enrollment Status: Completed
Publish Date: January 19, 2024
Intervention Type: Behavioral
Study Phase: Not Applicable
Randomized, Double-Blind, Phase II Trial of Vitamin D Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer
Randomized, Double-Blind, Phase II Trial of Vitamin D Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: April 26, 2022
Intervention Type: Drug, Dietary supplement
Study Phase: Phase 2
View 10 Less Clinical Trials

6 Total Publications

Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer: The Alliance A011502 Randomized Trial.
Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer: The Alliance A011502 Randomized Trial.
Journal: JAMA
Published: April 29, 2024
Similar Doctors
Expertise in
32
conditions
Dr. Frederick Lansigan
Hematology
Expertise in
32
conditions
Dr. Frederick Lansigan
Hematology

Mary Hitchcock Memorial Hospital

1 Medical Center Dr, 
Lebanon, NH 
 (48.8 miles away)
603-650-3792
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Frederick Lansigan is a Hematologist in Lebanon, New Hampshire. Dr. Lansigan is highly rated in 32 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia (CLL), Cutaneous T-Cell Lymphoma (CTCL), Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
21
conditions
Dr. Rachel Rosovsky
Hematology | Oncology
Expertise in
21
conditions
Dr. Rachel Rosovsky
Hematology | Oncology

Mass General Cancer Center At Newton-Wellesley

2014 Washington St, 
Newton, MA 
 (62.0 miles away)
617-219-1230
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Rachel Rosovsky is a Hematologist and an Oncologist in Newton, Massachusetts. Dr. Rosovsky is highly rated in 21 conditions, according to our data. Her top areas of expertise are Pulmonary Embolism, Venous Thromboembolism (VTE), Deep Vein Thrombosis, Embolectomy, and Thrombectomy.

Expertise in
43
conditions
Dr. Gina Divenuti
Hematology
Expertise in
43
conditions
Dr. Gina Divenuti
Hematology

Concord Hospital

250 Pleasant St, 
Concord, NH 
 (0.1 miles away)
603-224-2556
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Gina Divenuti is a Hematologist in Concord, New Hampshire. Dr. Divenuti is highly rated in 43 conditions, according to our data. Her top areas of expertise are Febrile Neutropenia, Chronic Familial Neutropenia, Paget Disease of the Breast, and Lymphofollicular Hyperplasia.

Frequently Asked Questions about Dr. Frederick Briccetti

How do I make an appointment with Dr. Frederick Briccetti?

You can book an appointment with Dr. Frederick Briccetti by calling their office at 603-224-2556. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Frederick Briccetti a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Frederick Briccetti is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Frederick Briccetti specialize in?

While Dr. Frederick Briccetti is a Hematology, they have specific expertise in Lung Cancer, Pleuropulmonary Blastoma, and Paget Disease of the Breast. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Frederick Briccetti participate in research or clinical trials?

Yes. Dr. Frederick Briccetti has published 6 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Frederick Briccetti's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Frederick Briccetti accept my insurance?

Dr. Frederick Briccetti accepts most major insurance plans, including Anthem BCBS and Blue Cross Blue Shield. We recommend calling the office directly at 603-224-2556 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Briccetti's expertise for a condition
ConditionClose
    View All 35 Advanced Conditions
    View All 127 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile